Batefenterol

Drug Profile

Batefenterol

Alternative Names: '081; 961081; Batefenterol succinate; GSK-961081; GSK-961081A; GSK-961081D; TD-5959

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Theravance
  • Developer GlaxoSmithKline
  • Class Biphenyl compounds; Bronchodilators; Carbamates; Carboxylic acids; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Jul 2016 GlaxoSmithKline completes a phase II trial for Chronic obstructive pulmonary disease in USA, Germany and South Africa (NCT02570165)
  • 01 Jun 2016 GlaxoSmithKline completes a phase I trial in healthy volunteers (alone and combination with fluticasone) in UK (NCT02666287)
  • 01 Mar 2016 GlaxoSmithKline completes a phase I pharmacokinetic trial in Healthy volunteers in United Kingdom (NCT02663089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top